[go: up one dir, main page]

CR20170315A - Inhibridores bace 1 selectivos - Google Patents

Inhibridores bace 1 selectivos

Info

Publication number
CR20170315A
CR20170315A CR20170315A CR20170315A CR20170315A CR 20170315 A CR20170315 A CR 20170315A CR 20170315 A CR20170315 A CR 20170315A CR 20170315 A CR20170315 A CR 20170315A CR 20170315 A CR20170315 A CR 20170315A
Authority
CR
Costa Rica
Prior art keywords
inhibridors
bace
selective
selective bace
compound
Prior art date
Application number
CR20170315A
Other languages
English (en)
Inventor
Erik James; Hembre
Jose Eduardo; Lopez
Simon James; Richards
Timothy Andrew; Woods
Jennifer Anne; Mcmahon
Leonard Larry Jr ; Winneroski
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20170315A publication Critical patent/CR20170315A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/08Malonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto de Fórmula II: o una sal aceptable para uso farmacéutico.
CR20170315A 2015-02-23 2016-02-17 Inhibridores bace 1 selectivos CR20170315A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562119391P 2015-02-23 2015-02-23
PCT/US2016/018160 WO2016137788A1 (en) 2015-02-23 2016-02-17 Selective bace1 inhibitors

Publications (1)

Publication Number Publication Date
CR20170315A true CR20170315A (es) 2017-08-14

Family

ID=55442893

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170315A CR20170315A (es) 2015-02-23 2016-02-17 Inhibridores bace 1 selectivos

Country Status (27)

Country Link
US (1) US9522923B2 (es)
EP (1) EP3262051B1 (es)
JP (1) JP6111001B1 (es)
KR (1) KR101945139B1 (es)
CN (1) CN107257801B (es)
AR (1) AR103680A1 (es)
AU (1) AU2016223072B2 (es)
BR (1) BR112017013936A2 (es)
CA (1) CA2972098A1 (es)
CL (1) CL2017002090A1 (es)
CO (1) CO2017008382A2 (es)
CR (1) CR20170315A (es)
DO (1) DOP2017000178A (es)
EA (1) EA031546B1 (es)
EC (1) ECSP17054980A (es)
GT (1) GT201700185A (es)
IL (1) IL252969A0 (es)
MX (1) MX367940B (es)
NZ (1) NZ732940A (es)
PE (1) PE20171337A1 (es)
PH (1) PH12017501523A1 (es)
SG (1) SG11201705764SA (es)
SI (1) SI3262051T1 (es)
TN (1) TN2017000355A1 (es)
TW (1) TWI627177B (es)
WO (1) WO2016137788A1 (es)
ZA (1) ZA201704293B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
EP3271356B1 (en) * 2015-03-19 2019-10-16 Eli Lilly and Company Selective bace1 inhibitors
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102359743B1 (ko) 2016-03-31 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌 유도체
KR102359735B1 (ko) 2016-03-31 2022-02-08 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
SG11201808237UA (en) 2016-04-01 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP2019530647A (ja) * 2016-08-18 2019-10-24 イーライ リリー アンド カンパニー Bace−1阻害剤と抗n3pglu aベータ抗体の併用療法
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US11407715B2 (en) 2017-05-22 2022-08-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
BR112019024311A2 (pt) 2017-05-22 2020-07-28 Janssen Pharmaceuticals, Inc. derivados de indolina substituídos como inibidores da replicação viral do dengue

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054617A1 (es) 2005-06-14 2007-07-04 Schering Corp Derivados de pirrol[3, 4 - d]pirimidina como inhibidores de aspartil proteasas y composiciones farmacéuticas que los comprenden
BRPI0906962B8 (pt) * 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
ES2738123T3 (es) 2008-06-13 2020-01-20 Shionogi & Co Derivado heterocíclico que contiene azufre que tiene actividad inhibitoria de ß-secretasa
US20110207723A1 (en) 2008-09-30 2011-08-25 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
WO2011071057A1 (ja) 2009-12-09 2011-06-16 塩野義製薬株式会社 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物
JPWO2011071109A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 アミノ基を有する縮合ヘテロ環化合物
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012162334A1 (en) 2011-05-24 2012-11-29 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
GB201212816D0 (en) * 2012-07-19 2012-09-05 Eisai Ltd Novel compounds
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
TWI639607B (zh) * 2013-06-18 2018-11-01 美國禮來大藥廠 Bace抑制劑
AR104241A1 (es) * 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos

Also Published As

Publication number Publication date
EA201791684A1 (ru) 2017-12-29
CN107257801A (zh) 2017-10-17
CL2017002090A1 (es) 2018-04-13
JP6111001B1 (ja) 2017-04-05
GT201700185A (es) 2018-11-23
SI3262051T1 (sl) 2019-11-29
US9522923B2 (en) 2016-12-20
EP3262051A1 (en) 2018-01-03
MX2017010861A (es) 2017-12-11
EA031546B1 (ru) 2019-01-31
AU2016223072B2 (en) 2018-11-15
NZ732940A (en) 2019-06-28
CA2972098A1 (en) 2016-09-01
PH12017501523A1 (en) 2018-02-05
IL252969A0 (en) 2017-08-31
TN2017000355A1 (en) 2019-01-16
KR101945139B1 (ko) 2019-02-01
ZA201704293B (en) 2019-01-30
CO2017008382A2 (es) 2017-11-30
TW201643170A (zh) 2016-12-16
JP2017511806A (ja) 2017-04-27
US20160244465A1 (en) 2016-08-25
WO2016137788A1 (en) 2016-09-01
DOP2017000178A (es) 2017-09-15
KR20170103971A (ko) 2017-09-13
CN107257801B (zh) 2019-08-13
SG11201705764SA (en) 2017-08-30
PE20171337A1 (es) 2017-09-13
AR103680A1 (es) 2017-05-24
TWI627177B (zh) 2018-06-21
AU2016223072A1 (en) 2017-07-13
MX367940B (es) 2019-09-12
ECSP17054980A (es) 2017-11-30
EP3262051B1 (en) 2019-10-02
BR112017013936A2 (pt) 2018-01-02

Similar Documents

Publication Publication Date Title
CR20170315A (es) Inhibridores bace 1 selectivos
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
HUE054815T2 (hu) 3,5-Difenil-diazol vegyületek vízoldható származékai
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
BR112018012325A2 (pt) métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída
MX381489B (es) Compuesto biciclico y uso del mismo para la inhibicion de suv39h2.
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.
DK3706710T3 (da) Formuleringer med forlænget frigivelse til intraartikulære anvendelser
EA201690908A1 (ru) Пиразолопиримидиновые соединения
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
MX379649B (es) Derivados de azetidina para formacion de imágenes de tau.
EA201791596A1 (ru) Пиразоловые соединения
TH1601001469A (es)